@article{0888a0f28f414438a8494b1b751ad797,
title = "Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study",
abstract = "Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Cross-Over Studies, Dexamethasone, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Pyrazines, Quality of Life, Recurrence, Thalidomide",
author = "Martin Hjorth and {\O}yvind Hjertner and Knudsen, \{Lene Meldgaard\} and Nina Gulbrandsen and Erik Holmberg and Pedersen, \{Per Tr{\o}llund\} and Andersen, \{Niels Frost\} and Bj{\"o}rn Andr{\'e}asson and Rolf Billstr{\"o}m and Kristina Carlson and Carlsson, \{Margaretha S\} and Max Flogeg{\aa}rd and Karin Forsberg and Peter Gimsing and Torbj{\"o}rn Karlsson and Olle Linder and Hareth Nahi and Annika Othz{\'e}n and Agneta Swedin and \{Nordic Myeloma Study Group (NMSG)\}",
note = "{\textcopyright} 2012 John Wiley \& Sons A/S.",
year = "2012",
doi = "10.1111/j.1600-0609.2012.01775.x",
language = "English",
volume = "88",
pages = "485--96",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "John Wiley and Sons Inc.",
number = "6",
}